Research programme: oncolytic cancer vaccines - Vyriad

Drug Profile

Research programme: oncolytic cancer vaccines - Vyriad

Alternative Names: Vesicular stomatitis virus vaccine - Vyriad; VSV-IFNβ-NIS - Vyriad

Latest Information Update: 09 Aug 2016

Price : $50

At a glance

  • Originator Omnis Pharma
  • Class Cancer vaccines; Oncolytic viruses
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 05 Aug 2016 Vyriad in-licenses STING technology from StingInn
  • 19 Jul 2016 Preclinical trials in Cancer in USA (Parenteral) (Vyraid pipeline, July 2016) before July 2016
  • 18 Mar 2016 Magnis Therapeutics has merged with Omnis Pharma to form Vyriad
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top